Breath Therapeutics Snapped Up Post Series A By Specialty Company Zambon

Italy’s privately held Zambon could pay up to €500m to bulk up its respiratory products pipeline, producing a nice return for Breath Therapeutics’ syndicate of European investors.  

Lungs
• Source: Shutterstock

Italy’s Zambon Co. SPA has paid an initial €140m to acquire the VC-backed German/US biotech, Breath Therapeutics Holding BV in a move that strengthens the specialty products pipeline of the mid-sized European pharmaceutical company, brings US-based clinical and regulatory expertise, and provides a significant return for investors in Breath Therapeutics, which raised €43.5m in a series A round in 2017.

The deal is the largest in Milan-headquartered Zambon’s history and adds a second potential therapeutic candidate to the company’s late-stage...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.